Preliminary fourth quarter neffy® net product revenue of approximately $6.5 million Preliminary cash, cash equivalents and ...

Alongside over-the-counter NARCAN® Nasal Spray 4 mg, prescription KLOXXADO® (naloxone HCl) Nasal Spray 8 mg will expand Emergent’s ability to ...

Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical group, today announces that it has entered an exclusive commercial partnership with Emergent BioSolutions (Emergent) for the sale of ...

Hikma Pharmaceuticals plc (HIK, HIK.L) announced Tuesday that it has entered an exclusive commercial partnership with Emergent ...

After its sudden rise and precipitous fall during the COVID-19 pandemic, Emergent BioSolutions is taking measured steps as it attempts to reestablish its unique role as a drug developer combating u | ...

Emergent BioSolutions (NYSE:EBS) has entered into an agreement for the exclusive commercial rights in the U.S. and Canada for ...

Even after a flurry of corporate updates during the first two days of the J.P. Morgan Healthcare Conference, many more ...

has added neffy® (epinephrine nasal spray) to its Commercial national formularies. This decision makes neffy broadly available to millions of their commercially insured patients across the country.

(epinephrine nasal spray) to its Commercial national formularies. This decision makes neffy broadly available to millions of their commercially insured patients across the country. neffy 2 mg is for ...

Emergent BioSolutions (EBS) announces that it has entered into an agreement to obtain exclusive commercial rights in the U.S. and Canada to Hikma ...